Epic Sciences introduces sensitive HRD liquid biopsy test for PARP inhibitor trial
Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency in individual circulating tumor cells. The test has already been incorporated into numerous clinical studies of HRD-targeted therapeutics. June 24, 2016